Neuronyx, Inc.
A development-stage biopharmaceutical company.
Neuronyx has developed a unique population of human adult bone marrow-derived stem cells (hABM-SCs) and processes for its isolation and expansion. The inability to expand adult stem cells to the quantities needed for clinical development and commercialization has been a major technical barrier associated with their pharmaceutical development.
Neuronyx can produce up to 2 x 1019 cells from a single bone marrow aspirate in four passages without the need for immortalizing agents or a murine feeder layer. This level of expansion should provide Neuronyx with the ability to produce commercial quantities of pharmaceutical-grade hABM-SCs.
Lead program is focused on the use of hABM-SCs for cardio-related disease applications. Studies demonstrate the preclinical efficacy of hABM-SCs in improving cardiac function following myocardial infarction. Additional studies are in progress.
Also conducting research relating to other indications including stroke, diabetes and liver disorders.
http://www.neuronyx.com/
